Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Retained Earnings (2016 - 2025)

Aptevo Therapeutics' Retained Earnings history spans 11 years, with the latest figure at -$269.2 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 11.59% year-over-year to -$269.2 million; the TTM value through Sep 2025 reached -$269.2 million, down 11.59%, while the annual FY2024 figure was -$247.6 million, 10.8% down from the prior year.
  • Retained Earnings for Q3 2025 was -$269.2 million at Aptevo Therapeutics, down from -$260.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$192.9 million in Q1 2021 and bottomed at -$269.2 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$217.5 million (2023), against an average of -$222.8 million.
  • The largest annual shift saw Retained Earnings decreased 16.92% in 2021 before it grew 8.34% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$214.1 million in 2021, then rose by 3.75% to -$206.0 million in 2022, then dropped by 8.45% to -$223.4 million in 2023, then dropped by 10.8% to -$247.6 million in 2024, then decreased by 8.74% to -$269.2 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Retained Earnings are -$269.2 million (Q3 2025), -$260.2 million (Q2 2025), and -$254.0 million (Q1 2025).